 |
|
The Effect of Early, Intensive Statin Therapy on Acute Coronary Syndrome
A Meta-analysis of Randomized Controlled Trials
Eddie Hulten, MD, MPH;
Jeffrey L. Jackson, MD, MPH;
Kevin Douglas, MD, MPH;
Susan George, MD;
Todd C. Villines, MD
Arch Intern Med. 2006;166:1814-1821.
Background In addition to well-established secondary prevention benefits for atherosclerotic coronary artery disease, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are hypothesized to have short-term benefit in acute coronary syndrome (ACS), yet the data are inconsistent, with some trials underpowered to demonstrate therapeutic benefit. Our objective was to determine the effects of early, intensive statin therapy for ACS.
Data Sources Studies found in the PubMed, MEDLINE, EMBASE, BIOSIS, SciSearch, PASCAL, and International Pharmaceutical Abstracts (IPA) databases and the Cochrane Controlled Trials Register published between January 1974 and May 2006.
Study Selection Randomized controlled trials of statins begun within 14 days of hospitalization for ACS were included.
Data Extraction Two investigators independently abstracted study quality, characteristics, and outcomes.
Data Synthesis Thirteen randomized controlled trials published before May 2006 were available, involving 17 963 adults (median number of patients, 135; median follow-up, 6 months). Early, intensive statin therapy for ACS decreased the rate of death and cardiovascular events over 2 years of follow-up (hazard ratio, 0.81 [95% confidence interval, 0.77-0.87]) (Q3 = 58.54; P<.001; I2 = 95%). Survival curves revealed that this benefit begins to occur between 4 and 12 months, achieving statistical significance by 12 months. There was no evidence of publication bias, and sensitivity analyses did not identify a dominating study or study characteristic.
Conclusions Early, intensive statin therapy reduces death and cardiovascular events after 4 months of treatment. The validity of this finding would be strengthened by an analysis of individual patient data.
Author Affiliations: Departments of Internal Medicine (Drs Hulten and George), General Internal Medicine (Drs Jackson and Douglas), and Cardiology (Dr Villines), Walter Reed Army Medical Center, Washington, DC; and Uniformed Services University of the Health Sciences, Bethesda, Md.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Statins in Acute Coronary Syndromes: Do the Guideline Recommendations Match the Evidence?
Morrissey et al.
J Am Coll Cardiol 2009;54:1425-1433.
ABSTRACT
| FULL TEXT
Preventing further vascular events after a stroke or transient ischaemic attack: an update on medical management
Sudlow
PN 2008;8:141-157.
ABSTRACT
| FULL TEXT
The Year in Non ST-Segment Elevation Acute Coronary Syndrome
Giugliano and Braunwald
J Am Coll Cardiol 2007;50:1386-1395.
FULL TEXT
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology
Authors/Task Force Members et al.
Eur Heart J 2007;28:1598-1660.
FULL TEXT
The Year in Atherothrombosis
Sanz et al.
J Am Coll Cardiol 2007;49:1740-1749.
FULL TEXT
Acute coronary syndromes, response to clopidogrel, and worsened cardiovascular outcomes: the hen and the egg dilemma
Serebruany
Eur Heart J 2007;28:640-641.
FULL TEXT
Evidently. . .
Lehman
Evid. Based Med. 2007;12:8-8.
FULL TEXT
Other articles noted
Evid. Based Med. 2007;12:31-32.
FULL TEXT
|
